HURACongressional Stock Trades
TuHURA Biosciences, Inc. Common Stock
Pharmaceutical Preparations
Congressional stock trades in TuHURA Biosciences, Inc. Common Stock (HURA) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
1
Politicians Trading
1
Last Traded
Jul 13, 2025
Price History
About TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.